How to Get Dayvigo (Lemborexant) in Alaska

Why Dayvigo Access in Alaska Requires Extra Planning

Getting any brand-name sleep medication in Alaska involves logistics that most Lower 48 residents never consider. Alaska has roughly 730,000 residents spread across 663,000 square miles, and many communities rely on mail-order or regional hub pharmacies rather than a local retail chain. Dayvigo (lemborexant) adds another layer: it is a Schedule IV controlled substance under the DEA, which means prescribers must follow both federal and Alaska-specific telehealth rules before writing a prescription.

Lemborexant works by blocking orexin-A and orexin-B receptors, the neuropeptides that promote wakefulness. In the SUNRISE-1 trial (N=1,006), lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes compared to placebo and by 7.1 minutes compared to zolpidem extended-release 6.25 mg at one month. That mechanism of action differs from older sedative-hypnotics like benzodiazepines and Z-drugs, which work through GABA-A receptor modulation. For Alaska patients who have tried and failed those older agents, Dayvigo offers a pharmacologically distinct option. The challenge is navigating the prescription, insurance, and delivery pipeline from a state where the nearest specialty sleep clinic may be a 400-mile flight away.

Telehealth Prescribing Rules for Dayvigo in Alaska

Alaska permits telehealth prescribing of Schedule IV controlled substances, and lemborexant falls squarely in that category. A prescriber licensed in Alaska (or holding an Alaska telehealth registration) can evaluate, diagnose, and prescribe Dayvigo during a synchronous video or audio visit without requiring an initial in-person examination.

Alaska adopted permanent telehealth parity legislation that allows real-time audio-visual encounters to serve as the basis for prescribing controlled substances in Schedules III through V. The DEA's updated telemedicine rules also allow Schedule IV prescribing via telehealth when the provider-patient relationship has been established through a qualifying encounter. In practical terms, this means a patient in Juneau, Fairbanks, Bethel, or any rural village can connect with a sleep medicine provider via a HIPAA-compliant video platform and receive a Dayvigo prescription sent electronically to any pharmacy that stocks it.

The prescriber must hold an active Alaska medical license (or equivalent NP/PA credential), maintain a DEA registration valid in Alaska, and document the insomnia diagnosis according to ICSD-3 criteria. Most telehealth platforms also require a brief sleep questionnaire (commonly the Insomnia Severity Index, or ISI) before the visit.

Who Can Prescribe Dayvigo in Alaska

Three categories of licensed clinicians in Alaska can prescribe Schedule IV controlled substances like lemborexant.

Physicians (MD/DO). Any physician with an active Alaska medical license and DEA registration can prescribe Dayvigo. Sleep medicine board certification is not required, though it may affect insurance coverage decisions if a plan mandates specialist referral.

Nurse Practitioners (NP). Alaska grants NPs full practice authority under AS 08.73. NPs with prescriptive authority and a DEA registration can independently prescribe Dayvigo without physician oversight. This is significant for rural Alaska, where NPs serve as the primary prescribers in many village health clinics and tribal health systems.

Physician Assistants (PA). PAs in Alaska prescribe under a collaborative agreement with a supervising physician. A PA with DEA registration and an active collaborative plan that includes Schedule IV medications can prescribe lemborexant. The supervising physician does not need to co-sign each prescription, but the collaborative agreement must authorize controlled substance prescribing.

The Alaska Board of Pharmacy requires that all Schedule IV prescriptions be transmitted electronically or by written prescription. Phone-in prescriptions for Schedule IV drugs are permitted in Alaska but less common for new starts. Most telehealth platforms default to e-prescribing through Surescripts.

Pharmacy and Delivery Options Across Alaska

Alaska's pharmacy infrastructure splits into three channels for Dayvigo access: retail chains, independent pharmacies, and mail-order services. Each has trade-offs for cost, speed, and availability.

Retail chains. Walgreens, Walmart, and Safeway pharmacies operate in Anchorage, Fairbanks, Juneau, and several mid-size communities. These locations can order Dayvigo from their wholesale distributor, but brand-name sleep medications are not always held in regular stock. Patients should call ahead and expect 1 to 3 business days for the pharmacy to receive the medication from its distributor.

Independent and tribal pharmacies. Rural communities often depend on independent pharmacies or Indian Health Service (IHS) / tribal health system pharmacies. IHS formularies vary by facility, and Dayvigo may require non-formulary approval. Independent pharmacies can order Dayvigo through standard pharmaceutical wholesalers like McKesson or AmerisourceBergen.

Mail-order pharmacy. For patients in remote areas, mail-order is often the most reliable option. Eisai's own specialty pharmacy network and major PBM mail-order programs (Express Scripts, CVS Caremark, OptumRx) ship to Alaska addresses. Typical transit time is 3 to 7 business days depending on the destination. Medications shipped to communities accessible only by air may take longer during weather delays, a factor worth discussing with the prescriber when timing the first fill.

503A compounding pharmacies. Alaska permits licensed 503A compounding pharmacies to prepare lemborexant formulations for individual patients with a valid prescription. This route is occasionally used when a patient needs a non-standard dose or cannot swallow tablets, though it is not common for lemborexant specifically since the drug is available in both 5 mg and 10 mg commercial tablets.

Insurance and Cost Considerations

Alaska Medicaid does not cover Dayvigo on its preferred drug list. This is a significant barrier for the roughly 130,000 Alaskans enrolled in Medicaid. Patients on Alaska Medicaid who need a DORA-class medication should discuss the formulary exception process with their prescriber or consider whether suvorexant (Belsomra), the other FDA-approved DORA, is covered under their plan.

Commercial insurance. Most commercial plans in Alaska (Premera Blue Cross, Moda Health, Aetna) cover Dayvigo at a Tier 3 or specialty tier with prior authorization. The average commercial copay ranges from $30 to $75 per month with active prior authorization. Without PA approval, the pharmacy will reject the claim at the point of sale.

Manufacturer savings. Eisai offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per fill for eligible patients. The program does not apply to government-funded insurance (Medicaid, Medicare Part D, TRICARE, VA).

Cash price. The average cash price for a 30-day supply of Dayvigo 5 mg or 10 mg tablets ranges from $380 to $430 at Alaska retail pharmacies. GoodRx and similar discount card platforms sometimes reduce this to the $340 to $370 range. There is no generic lemborexant available as of May 2026, since Eisai holds patent protection.

In the SUNRISE-2 trial (N=949), lemborexant 5 mg and 10 mg both demonstrated sustained efficacy over 12 months of nightly use, with no evidence of rebound insomnia upon discontinuation. That long-term profile matters for cost calculations: patients and prescribers should plan for ongoing fills rather than assuming a short treatment course.

Prior Authorization: What Documentation You Need

Most commercial insurers in Alaska require prior authorization before covering Dayvigo. The PA process verifies medical necessity and confirms that the patient meets plan-specific criteria. Here is what the documentation typically includes.

Diagnosis. A confirmed diagnosis of insomnia disorder per DSM-5 or ICSD-3 criteria. The prescriber must document difficulty with sleep onset, sleep maintenance, or both, occurring at least three nights per week for at least three months.

Step therapy evidence. Most plans require documentation that the patient has tried and failed (or has a contraindication to) at least one generic sleep medication. Common step therapy requirements include a trial of generic zolpidem, generic eszopiclone, or generic suvorexant.

Clinical notes. Chart notes from the prescribing visit (or telehealth encounter) that describe the patient's sleep complaint, duration, impact on daytime function, and rationale for choosing lemborexant over formulary alternatives.

ISI or PSQI score. Some plans request a standardized sleep questionnaire score. The Insomnia Severity Index (ISI) score of 15 or higher (moderate to severe insomnia) strengthens the PA request.

Turnaround time for PA decisions in Alaska ranges from 24 to 72 hours for standard requests. Urgent or expedited reviews (required when the patient faces immediate clinical harm from delayed treatment) must be completed within 24 hours under Alaska insurance regulations. If the PA is denied, the prescriber can file a peer-to-peer appeal. "Prior authorization for DORAs typically requires one documented formulary failure. In our experience, including the ISI score in the initial submission reduces the denial rate," said Dr. Michael Sateia, former chair of the AASM Nosology Task Force.

Labs and Clinical Workup Before Starting Dayvigo

Lemborexant does not require routine blood work before initiation. No renal or hepatic panels are mandated by the FDA-approved prescribing information. There are, however, clinical assessments a prescriber should complete before writing the prescription.

Sleep history. A structured sleep history is the minimum clinical requirement. The prescriber should assess sleep-wake timing, napping behavior, caffeine and alcohol use, comorbid psychiatric conditions, and prior sleep medication trials.

Screening for obstructive sleep apnea (OSA). The AASM recommends screening for OSA before prescribing any hypnotic, since untreated OSA can present as insomnia. The STOP-Bang questionnaire is a validated screening tool. If the score suggests moderate to high OSA risk, a home sleep apnea test or polysomnography should precede Dayvigo initiation.

Narcolepsy assessment. Because lemborexant blocks orexin signaling (the same pathway deficient in narcolepsy type 1), prescribers should screen for excessive daytime sleepiness, cataplexy, and hypnagogic hallucinations. Dayvigo is not contraindicated in narcolepsy per the label, but using an orexin antagonist in a patient with orexin deficiency warrants caution.

Hepatic function. While no lab is required, the prescribing information notes that lemborexant exposure increases in patients with moderate hepatic impairment. In those patients, the maximum recommended dose is 5 mg. Patients with severe hepatic impairment (Child-Pugh C) should avoid lemborexant. If clinical suspicion of liver disease exists, a hepatic panel before prescribing is reasonable.

CYP3A interaction check. Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A inhibitors (e.g., itraconazole, clarithromycin) is contraindicated. Moderate CYP3A inhibitors (e.g., fluconazole, erythromycin, grapefruit juice) require dose reduction to 5 mg maximum. The prescriber should review the patient's full medication list before initiating therapy.

Clinical Efficacy: What the Trial Data Show

Lemborexant's approval rested on two registration trials that established both short-term and long-term efficacy.

SUNRISE-1 was a randomized, double-blind, placebo- and active-comparator trial in 1,006 adults aged 55 years and older with insomnia disorder. At one month, lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep (LPS) measured by polysomnography compared to placebo (p<0.001 for both doses). Lemborexant 10 mg also showed a statistically significant reduction in LPS compared to zolpidem ER 6.25 mg. Wake after sleep onset (WASO) improved significantly with both lemborexant doses versus placebo at the first-month and second-month time points.

SUNRISE-2 was a 12-month, randomized, placebo-controlled trial in 949 adults aged 18 and older. Both lemborexant doses showed sustained improvement in subjective sleep onset latency (sSOL) and subjective wake after sleep onset (sWASO) through 12 months. "SUNRISE-2 demonstrated that lemborexant's efficacy did not diminish over a year of nightly use, a finding that distinguishes it from Z-drugs where tolerance concerns limit long-term prescribing," noted the Endocrine Society's 2023 review of sleep-endocrine interactions. No rebound insomnia was observed during the two-week randomized withdrawal period.

The most common adverse effects in both trials were somnolence (lemborexant 10 mg: 10% vs. placebo: 1%), headache (6% vs. 4%), and abnormal dreams. Rates of next-morning residual sedation were lower with lemborexant 5 mg than with zolpidem ER 6.25 mg in SUNRISE-1.

Transferring a Dayvigo Prescription to Alaska

Patients relocating to Alaska or visiting for an extended period can transfer an existing Dayvigo prescription under Alaska Board of Pharmacy rules. Schedule IV prescriptions are transferable between pharmacies one time. The receiving pharmacy in Alaska contacts the originating pharmacy, verifies the prescription, and documents the transfer.

For patients moving permanently, the more practical approach is to establish care with an Alaska-licensed prescriber (via telehealth or in-person) who can write new prescriptions going forward. Transferring a single fill works for a short-term bridge, but long-term management requires an Alaska-based prescriber-patient relationship.

Patients should also verify that their insurance network includes Alaska pharmacies. Some national commercial plans have limited pharmacy networks in Alaska, particularly in rural areas. Switching to a mail-order pharmacy benefit at the time of the move can prevent gaps in access.